<DOC>
	<DOCNO>NCT01576887</DOCNO>
	<brief_summary>This study multi-center , double-blinded , randomize , study bardoxolone methyl treatment patient End-Stage Renal Disease ( ERSD ) Type 2 Diabetes Mellitus ( T2DM ) peritoneal dialysis .</brief_summary>
	<brief_title>A Double-Blind , Randomized , Placebo-Controlled Safety Study Evaluating Effects Residual Renal Function ( RFF ) Patients With End-Stage Renal Disease Type 2 Diabetes Mellitus Peritoneal Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>1 . Patients must ESRD PD longer 3 month 2 . Patients must diagnosis T2DM prior start dialysis 3 . Patients must RRF , define mean urea creatinine clearance 24 hour urine collection , ≥ 25 Liters/week/1.73 m2 document four month prior Screen A visit 4 . Patients must RRF , define mean urea creatinine clearance 24 hour urine collection , ≥ 25 Liters/week/1.73 m2 Screen A Screen B visit 5 . The RRF value obtain Screen B visit , must less 50 % RRF value obtain Screen A visit 6 . Patients must least 18 year age 7 . Patients must mean systolic blood pressure ( SBP ) three reading Screen A Screen B visit ≤ 160 mmHg ≥ 90 mmHg 8 . Patients must mean diastolic blood pressure ( DBP ) three reading Screen A Screen B visit &lt; 100 mmHg ≥ 40 mmHg 9 . Patients must willing practice method birth control ( male partner childbearing potential female childbearing potential ) screening , take study drug least 30 day last dose study drug ingest 10 . Patients must willing able cooperate aspect protocol 11 . Patients must willing able give write informed consent participate study . They must provide consent access medical data accord appropriate local data protection legislation allow authorization access medical record describe event capture endpoint 1 . History Autosomal Dominant Polycystic Kidney Disease 2 . Currently Active Systemic Lupus Erythematosus 3 . History Hepatitis B Surface Antigen + 4 . History Hepatitis C Antibody + treat antiviral therapy 5 . History organ transplant 6 . A planned renal transplant live donor study 7 . History hospitalization congestive heart failure pulmonary edema within 12 week study randomization 8 . History cirrhosis liver 9 . History amyloidosis light chain nephropathy 10 . History hemoglobin A1c level &gt; 11.0 % ( 97 mmol/mol ) within 12 week study randomization 11 . History recently active cardiovascular disease define : 1 . Unstable angina pectoris within 12 week study randomization 2 . Myocardial infarction , coronary artery bypass graft surgery , percutaneous transluminal coronary angioplasty/stent within 12 week study randomization 3 . Cerebrovascular accident , include transient ischemic attack within 12 week study randomization 12 . History diagnostic interventional procedure require intravenous administration iodinate contrast agent gadolinium within 12 week study randomization 13 . History know severe obstructive valvular heart disease severe obstructive hypertrophic cardiomyopathy 14 . History know 2o 3o atrioventricular block successfully treat pacemaker 15 . History resuscitate sudden cardiac death 16 . History automatic implantable defibrillator 17 . QTc great 0.50 second ECG obtain either Screen A Screen B visit 18 . A serum magnesium level le 1.4 meq/L either Screen A Screen B visit laboratory test result 19 . History systemic immunosuppression 15 day , cumulatively , within 12 week prior study randomization anticipate need 15 day immunosuppression study 20 . Total bilirubin , aspartate transaminase ( AST ) , alanine transaminase ( ALT ) level great upper limit normal ( ULN ) alkaline phosphatase level great two time ULN either Screen A Screen B visit laboratory test result 21 . Known hypersensitivity component study drug 22 . Current history drug alcohol abuse , assess investigator 23 . History clinically significant infection require intravenous administration antibiotic hospitalization within 12 week study randomization 24 . In patient peritoneal dialysis ≥ 6 month , two episode peritonitis 6 month study randomization . In patient peritoneal dialysis &lt; 6 month , one episode peritonitis study randomization 25 . History diagnosis treatment malignancy past 5 year , exclude nonmelanoma skin cancer carcinoma situ cervix 26 . History clinical condition , judgment investigator , could potentially pose health risk patient involve study 27 . Patient unable communicate cooperate investigator due language problem , poor mental development , impaired cerebral function 28 . Participation clinical study involve intervention within 30 day prior Screen A visit , concurrent participation study , participation prior clinical study involve bardoxolone methyl form 29 . Female patient pregnant , intend become pregnant study , nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>